Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Date:12/12/2012

ectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. The program also includes a study in patients who have or are at high risk for developing cardiovascular disease, called the CANagliflozin cardioVascular Assessment Study (CANVAS).

Janssen presented data from Phase 3 studies at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) in Barcelona in November.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. has marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand and parts of Asia.

About Type 2 Diabetes

Type 2 diabetes is a chronic condition that affects the body's ability to metabolize sugar, or glucose, and is characterized by the inability of pancreatic beta cell function to keep up with the body's demand for insulin. People with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. In most people with type 2 diabetes, obesity causes resistance of the body to the action of insulin and if the pancreatic beta cell cannot produce enough insulin, hyperglycemia and type 2 diabetes ensue.

If left uncontrolled, type 2 diabetes can lead to serious long-term microvascular complications such as nerve disease leading to amputation, retinopathy resulting in blindness and nephropathy causing end-stage renal disease. Improved gl
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... More than 3,500 attendees from top pharmaceutical, fine chemical ... conference, which includes on-site education sessions, daily networking events ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ... need for oxygen when air is thin," states Dr Barnes. She ...
(Date:1/14/2014)... WASHINGTON, New York , January 14, ... http://www.equashield.com ), the leading provider of Closed System Transfer Devices (CSTD) ... has achieved 60% year-over-year sales growth for ... Equashield,s closed systems reduce the risk of ... other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... IPSWICH, Mass., April 12, 2011 New England Biolabs ... of reagents for life science research, announces that it ... the Netherlands, and Imperial Life Sciences (ILS), based in ... BIOKE, a Cell Signaling Technology (CST) Europe ...
... leading EchoStim® Echogenic Insulated needle has been improved. ... Blocks (PNBs) using nerve stimulation and ultrasound guidance ... has more, brighter, easier to see reflectors, which ... the benefits of using both nerve block techniques ...
Cached Medicine Technology:New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... WASHINGTON, May 12 A new report from ... medications for a variety of diseases often are ... and Asian Americans. This comprehensive review of studies ... Origins and Strategies for Addressing Ethnic and ...
... the personal injury attorney firm in Manhattan, is standing up against insurance ... ... 2009 -- New York personal injury lawyers can have a ... business. When it comes to frivolous lawsuits, these monsters want the public ...
... President of CanReg Inc., is pleased to announce that ... Executive Advisory Strategist to assist client firms with their ... with small to medium sized public and private biotechnology ... been on directing and managing regulatory affairs, most recently ...
... other strains of influenza, CDC says , , TUESDAY, May 12 ... seeing some complications among pregnant women as the swine flu ... at higher risk of complications of influenza, whether it,s the ... seeing some severe complications in women with this year,s novel ...
... The Pennsylvania Department of Aging and the Office of ... Council that will advise on new policies and procedures to ... citizens and those with disabilities prefer to live independently and ... so we want to make sure that the services we ...
... (Nasdaq: VOLC ), a leader in the ... and treatment of coronary and peripheral artery disease, said ... Annual JMP Securities Research Conference on Monday, May 18.The ... at 3:00 p.m., Pacific Daylight Time (6:00 p.m., Eastern ...
Cached Medicine News:Health News:Report Reveals Disparities in Pharmaceutical Treatment for Minority Patients 2Health News:Report Reveals Disparities in Pharmaceutical Treatment for Minority Patients 3Health News:Report Reveals Disparities in Pharmaceutical Treatment for Minority Patients 4Health News:Manhattan Personal Injury Attorney Blames Insurance Industry For Negative Perception Of Civil Justice System 2Health News:Swine Flu May Pose Problems for Pregnant Women 2Health News:Swine Flu May Pose Problems for Pregnant Women 3Health News:Swine Flu May Pose Problems for Pregnant Women 4Health News:Swine Flu May Pose Problems for Pregnant Women 5Health News:Swine Flu May Pose Problems for Pregnant Women 6Health News:Swine Flu May Pose Problems for Pregnant Women 7Health News:Swine Flu May Pose Problems for Pregnant Women 8Health News:Swine Flu May Pose Problems for Pregnant Women 9Health News:Pennsylvania Council Formed to Advise on Improving Services to Older Adults, People with Disabilities 2Health News:Volcano Corporation Presentation at JMP Conference to be Webcast 2
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
Mylar Plate Sealers 100/Box...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
For use with 96-well plates, catalog # 410150...
Medicine Products: